NASDAQ:PRE Prenetics Global (PRE) Stock Price, News & Analysis $5.42 +0.07 (+1.21%) Closing price 02/21/2025 03:57 PM EasternExtended Trading$5.55 +0.14 (+2.49%) As of 02/21/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Prenetics Global Stock (NASDAQ:PRE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Prenetics Global alerts:Sign Up Key Stats Today's Range$5.33▼$5.5050-Day Range$5.09▼$6.0052-Week Range$2.85▼$7.84Volume1,188 shsAverage Volume17,097 shsMarket Capitalization$66.06 millionP/E RatioN/ADividend YieldN/APrice Target$9.00Consensus RatingBuy Company OverviewPrenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong.Read More… Prenetics Global Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScorePRE MarketRank™: Prenetics Global scored higher than 60% of companies evaluated by MarketBeat, and ranked 406th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPrenetics Global has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePrenetics Global has only been the subject of 1 research reports in the past 90 days.Read more about Prenetics Global's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prenetics Global are expected to grow in the coming year, from ($3.30) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prenetics Global is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prenetics Global is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrenetics Global has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Prenetics Global's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.40% of the float of Prenetics Global has been sold short.Short Interest Ratio / Days to CoverPrenetics Global has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prenetics Global has recently decreased by 24.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrenetics Global does not currently pay a dividend.Dividend GrowthPrenetics Global does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.40% of the float of Prenetics Global has been sold short.Short Interest Ratio / Days to CoverPrenetics Global has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Prenetics Global has recently decreased by 24.71%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.43 News SentimentPrenetics Global has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Prenetics Global this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prenetics Global insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Prenetics Global is held by insiders.Percentage Held by InstitutionsOnly 25.01% of the stock of Prenetics Global is held by institutions.Read more about Prenetics Global's insider trading history. Receive PRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prenetics Global and its competitors with MarketBeat's FREE daily newsletter. Email Address PRE Stock News HeadlinesPositiveID (OTCMKTS:PSID) & Prenetics Global (NASDAQ:PRE) Critical ReviewFebruary 20 at 2:23 AM | americanbankingnews.comCritical Contrast: Prenetics Global (NASDAQ:PRE) and Cytek Biosciences (NASDAQ:CTKB)February 16, 2025 | americanbankingnews.comElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One Boston based think tank believes it could have drastic impacts on your money and life in America.February 22, 2025 | Altimetry (Ad)Financial Comparison: Bio-Rad Laboratories (NYSE:BIO) vs. Prenetics Global (NASDAQ:PRE)February 15, 2025 | americanbankingnews.comNYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 14th + KARMAN POPS DOUBLE DIGIT IPOFebruary 14, 2025 | prnewswire.comPrenetics Global Ltd trading resumesFebruary 12, 2025 | markets.businessinsider.comPrenetics Global Ltd trading halted, volatility trading pauseFebruary 12, 2025 | markets.businessinsider.comPrenetics partners with Humanity Protocol, launches crypto strategic reserveFebruary 11, 2025 | markets.businessinsider.comSee More Headlines PRE Stock Analysis - Frequently Asked Questions How have PRE shares performed this year? Prenetics Global's stock was trading at $5.80 at the beginning of 2025. Since then, PRE shares have decreased by 6.6% and is now trading at $5.4150. View the best growth stocks for 2025 here. How were Prenetics Global's earnings last quarter? Prenetics Global Limited (NASDAQ:PRE) issued its quarterly earnings data on Wednesday, November, 27th. The company reported ($0.84) earnings per share (EPS) for the quarter. Prenetics Global had a negative net margin of 191.73% and a negative trailing twelve-month return on equity of 16.45%. When did Prenetics Global's stock split? Prenetics Global shares reverse split on the morning of Tuesday, November 14th 2023. The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Prenetics Global's major shareholders? Top institutional investors of Prenetics Global include Quinn Opportunity Partners LLC (0.10%). How do I buy shares of Prenetics Global? Shares of PRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prenetics Global own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prenetics Global investors own include Arista Networks (ANET), Adobe (ADBE), Broadcom (AVGO), NVIDIA (NVDA), Intuit (INTU), Arch Capital Group (ACGL) and Celestica (CLS). Company Calendar Last Earnings11/27/2024Today2/22/2025Next Earnings (Estimated)4/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:PRE CUSIPN/A CIK1876431 Webwww.prenetics.com Phone852-2210-9588FaxN/AEmployees1Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+66.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,720,000.00 Net Margins-191.73% Pretax Margin-176.67% Return on Equity-16.45% Return on Assets-13.34% Debt Debt-to-Equity RatioN/A Current Ratio1.40 Quick Ratio1.22 Sales & Book Value Annual Sales$21.74 million Price / Sales3.04 Cash FlowN/A Price / Cash FlowN/A Book Value$17.22 per share Price / Book0.31Miscellaneous Outstanding Shares12,200,000Free Float11,253,000Market Cap$66.06 million OptionableNot Optionable Beta-0.31 10 Best Stocks to Own in 2025Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:PRE) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prenetics Global Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Prenetics Global With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.